Time since menopause does not affect plasma viscosity, plasma thromboxane levels and Doppler findings

Fulvia Mancini, Nicola Persico, Giorgia Regnani, Annibale Volpe, Cesare Battaglia, Domenico De Aloysio

Research output: Contribution to journalArticle

Abstract

Objectives. To evaluate whether the use of transdermal hormone replacement therapy (HRT), in women within 5 years of menopause compared with women who were postmenopausal for > 5 years, would significantly influence thromboxane B2 levels, plasma viscosity and Doppler flow parameters at the level of the uterine, internal carotid, ophthalmic and bladder wall arteries. Methods. Thirty-five normal-weight (body mass index > 19 and <25 kg/m2) postmenopausal women (age 54.6 ± 3.9 years, mean ± standard deviation) participated in the study and were divided into two groups (Group I: w = 19, time since menopause <5 years; and Group II: n = 16, time since menopause > 5 years). Patients were treated with a continuous estradiol transdermal supplementation and 12-day courses of medroxyprogesterone acetate every 2 months. They were studied at baseline and after 6 months (in the estrogen-only phase of the cycle). Results. Results showed a beneficial effect of hormone substitution after 6 months of therapy. Baseline plasma viscosity was similar in both groups, and decreased significantly after therapy in both Group I (-17.5%) and Group II (-15.6%). Plasma levels of thromboxane B2 were similar at baseline and diminished equally in Group I and Group II (-85.6% and -85.2%, respectively) after treatment. Doppler assessment of the pulsatility index at the level of uterine, internal carotid, ophthalmic and bladder wall arteries showed no differences between groups at baseline and revealed a significant reduction of vascular impedance at the end of the treatment in both groups. Conclusions. Time since menopause does not affect the ootential hemodvnamic benefits of HRT in normal-weight women.

Original languageEnglish
Pages (from-to)170-175
Number of pages6
JournalGynecological Endocrinology
Volume20
Issue number3
DOIs
Publication statusPublished - Mar 2005

Fingerprint

Thromboxanes
Menopause
Viscosity
Thromboxane B2
Hormone Replacement Therapy
Urinary Bladder
Arteries
Weights and Measures
Medroxyprogesterone Acetate
Therapeutics
Electric Impedance
Blood Vessels
Estradiol
Estrogens
Body Mass Index
Hormones

Keywords

  • Doppler
  • Hormone replacement therapy
  • Plasma viscosity
  • Thromboxane
  • Time since menopause

ASJC Scopus subject areas

  • Endocrinology
  • Obstetrics and Gynaecology

Cite this

Time since menopause does not affect plasma viscosity, plasma thromboxane levels and Doppler findings. / Mancini, Fulvia; Persico, Nicola; Regnani, Giorgia; Volpe, Annibale; Battaglia, Cesare; De Aloysio, Domenico.

In: Gynecological Endocrinology, Vol. 20, No. 3, 03.2005, p. 170-175.

Research output: Contribution to journalArticle

Mancini, Fulvia ; Persico, Nicola ; Regnani, Giorgia ; Volpe, Annibale ; Battaglia, Cesare ; De Aloysio, Domenico. / Time since menopause does not affect plasma viscosity, plasma thromboxane levels and Doppler findings. In: Gynecological Endocrinology. 2005 ; Vol. 20, No. 3. pp. 170-175.
@article{a074b5ed8b324fb9bd2daa08e28137c6,
title = "Time since menopause does not affect plasma viscosity, plasma thromboxane levels and Doppler findings",
abstract = "Objectives. To evaluate whether the use of transdermal hormone replacement therapy (HRT), in women within 5 years of menopause compared with women who were postmenopausal for > 5 years, would significantly influence thromboxane B2 levels, plasma viscosity and Doppler flow parameters at the level of the uterine, internal carotid, ophthalmic and bladder wall arteries. Methods. Thirty-five normal-weight (body mass index > 19 and <25 kg/m2) postmenopausal women (age 54.6 ± 3.9 years, mean ± standard deviation) participated in the study and were divided into two groups (Group I: w = 19, time since menopause <5 years; and Group II: n = 16, time since menopause > 5 years). Patients were treated with a continuous estradiol transdermal supplementation and 12-day courses of medroxyprogesterone acetate every 2 months. They were studied at baseline and after 6 months (in the estrogen-only phase of the cycle). Results. Results showed a beneficial effect of hormone substitution after 6 months of therapy. Baseline plasma viscosity was similar in both groups, and decreased significantly after therapy in both Group I (-17.5{\%}) and Group II (-15.6{\%}). Plasma levels of thromboxane B2 were similar at baseline and diminished equally in Group I and Group II (-85.6{\%} and -85.2{\%}, respectively) after treatment. Doppler assessment of the pulsatility index at the level of uterine, internal carotid, ophthalmic and bladder wall arteries showed no differences between groups at baseline and revealed a significant reduction of vascular impedance at the end of the treatment in both groups. Conclusions. Time since menopause does not affect the ootential hemodvnamic benefits of HRT in normal-weight women.",
keywords = "Doppler, Hormone replacement therapy, Plasma viscosity, Thromboxane, Time since menopause",
author = "Fulvia Mancini and Nicola Persico and Giorgia Regnani and Annibale Volpe and Cesare Battaglia and {De Aloysio}, Domenico",
year = "2005",
month = "3",
doi = "10.1080/09513590400027273",
language = "English",
volume = "20",
pages = "170--175",
journal = "Gynecological Endocrinology",
issn = "0951-3590",
publisher = "Informa Healthcare",
number = "3",

}

TY - JOUR

T1 - Time since menopause does not affect plasma viscosity, plasma thromboxane levels and Doppler findings

AU - Mancini, Fulvia

AU - Persico, Nicola

AU - Regnani, Giorgia

AU - Volpe, Annibale

AU - Battaglia, Cesare

AU - De Aloysio, Domenico

PY - 2005/3

Y1 - 2005/3

N2 - Objectives. To evaluate whether the use of transdermal hormone replacement therapy (HRT), in women within 5 years of menopause compared with women who were postmenopausal for > 5 years, would significantly influence thromboxane B2 levels, plasma viscosity and Doppler flow parameters at the level of the uterine, internal carotid, ophthalmic and bladder wall arteries. Methods. Thirty-five normal-weight (body mass index > 19 and <25 kg/m2) postmenopausal women (age 54.6 ± 3.9 years, mean ± standard deviation) participated in the study and were divided into two groups (Group I: w = 19, time since menopause <5 years; and Group II: n = 16, time since menopause > 5 years). Patients were treated with a continuous estradiol transdermal supplementation and 12-day courses of medroxyprogesterone acetate every 2 months. They were studied at baseline and after 6 months (in the estrogen-only phase of the cycle). Results. Results showed a beneficial effect of hormone substitution after 6 months of therapy. Baseline plasma viscosity was similar in both groups, and decreased significantly after therapy in both Group I (-17.5%) and Group II (-15.6%). Plasma levels of thromboxane B2 were similar at baseline and diminished equally in Group I and Group II (-85.6% and -85.2%, respectively) after treatment. Doppler assessment of the pulsatility index at the level of uterine, internal carotid, ophthalmic and bladder wall arteries showed no differences between groups at baseline and revealed a significant reduction of vascular impedance at the end of the treatment in both groups. Conclusions. Time since menopause does not affect the ootential hemodvnamic benefits of HRT in normal-weight women.

AB - Objectives. To evaluate whether the use of transdermal hormone replacement therapy (HRT), in women within 5 years of menopause compared with women who were postmenopausal for > 5 years, would significantly influence thromboxane B2 levels, plasma viscosity and Doppler flow parameters at the level of the uterine, internal carotid, ophthalmic and bladder wall arteries. Methods. Thirty-five normal-weight (body mass index > 19 and <25 kg/m2) postmenopausal women (age 54.6 ± 3.9 years, mean ± standard deviation) participated in the study and were divided into two groups (Group I: w = 19, time since menopause <5 years; and Group II: n = 16, time since menopause > 5 years). Patients were treated with a continuous estradiol transdermal supplementation and 12-day courses of medroxyprogesterone acetate every 2 months. They were studied at baseline and after 6 months (in the estrogen-only phase of the cycle). Results. Results showed a beneficial effect of hormone substitution after 6 months of therapy. Baseline plasma viscosity was similar in both groups, and decreased significantly after therapy in both Group I (-17.5%) and Group II (-15.6%). Plasma levels of thromboxane B2 were similar at baseline and diminished equally in Group I and Group II (-85.6% and -85.2%, respectively) after treatment. Doppler assessment of the pulsatility index at the level of uterine, internal carotid, ophthalmic and bladder wall arteries showed no differences between groups at baseline and revealed a significant reduction of vascular impedance at the end of the treatment in both groups. Conclusions. Time since menopause does not affect the ootential hemodvnamic benefits of HRT in normal-weight women.

KW - Doppler

KW - Hormone replacement therapy

KW - Plasma viscosity

KW - Thromboxane

KW - Time since menopause

UR - http://www.scopus.com/inward/record.url?scp=18844462482&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18844462482&partnerID=8YFLogxK

U2 - 10.1080/09513590400027273

DO - 10.1080/09513590400027273

M3 - Article

C2 - 16019357

AN - SCOPUS:18844462482

VL - 20

SP - 170

EP - 175

JO - Gynecological Endocrinology

JF - Gynecological Endocrinology

SN - 0951-3590

IS - 3

ER -